WSGR logoWSGR logo
WSGR logo
  • Experience
  • People
  • Insights
  • About Us
  • Careers

  • Practice Areas
  • Industries

  • Corporate
  • Intellectual Property
  • Litigation
  • Patents and Innovations
  • Regulatory
  • Technology Transactions

  • Capital Markets
  • Corporate Governance
  • Corporate Life Sciences
  • Derivatives
  • Emerging Companies and Venture Capital
  • Employee Benefits and Compensation
  • Energy and Climate Solutions
  • Executive Advisory Program
  • Finance and Structured Finance
  • Fund Formation
  • Greater China
  • Mergers & Acquisitions
  • Private Equity
  • Public Company Representation
  • Real Estate
  • Restructuring
  • Shareholder Engagement and Activism
  • Tax
  • U.S. Expansion
  • Wealthtech

  • Special Purpose Acquisition Companies (SPACs)

  • Environmental, Social, and Governance

  • AI and Data Center Infrastructure
  • Energy Regulation and Competition
  • Project Development and M&A
  • Project Finance and Tax Credit Transactions
  • Sustainability and Decarbonization
  • Transportation Electrification

  • U.S. Expansion Library and Resources

  • Post-Grant Review
  • Trademark and Advertising

  • Antitrust Litigation
  • Arbitration
  • Board and Internal Investigations
  • Class Action Litigation
  • Commercial Litigation
  • Consumer Litigation
  • Corporate Governance Litigation
  • Employment Litigation
  • Executive Branch Updates
  • Government Investigations
  • Internet Strategy and Litigation
  • Patent Litigation
  • Securities Litigation
  • State Attorneys General
  • Supreme Court and Appellate Practice
  • Trade Secret Litigation
  • Trademark and Copyright Litigation
  • Trial
  • White Collar Crime

  • Advertising, Promotions, and Marketing
  • Antitrust and Competition
  • Committee on Foreign Investment in the U.S. (CFIUS)
  • Communications
  • Data, Privacy, and Cybersecurity
  • Export Control and Sanctions
  • FCPA and Anti-Corruption
  • FDA Regulatory, Healthcare, and Consumer Products
  • Federal Trade Commission
  • Fintech and Financial Services
  • Government Contracts
  • National Security and Trade
  • Payments
  • State Attorneys General
  • Strategic Risk and Crisis Management
  • Tariffs, Customs, and Import Compliance

  • Antitrust and Intellectual Property
  • Antitrust Civil Enforcement
  • Antitrust Compliance and Business Strategy
  • Antitrust Criminal Enforcement
  • Antitrust Litigation
  • Antitrust Merger Clearance
  • European Competition Law
  • Third-Party Merger and Non-Merger Antitrust Representation

  • Anti-Money Laundering
  • Foreign Ownership, Control, or Influence (FOCI)
  • Team Telecom

  • AI in Healthcare
  • Animal Health
  • Artificial Intelligence and Machine Learning
  • Aviation
  • Biotech
  • Blockchain and Cryptocurrency
  • Clean Energy
  • Climate and Clean Technologies
  • Communications and Networking
  • Consumer Products and Services
  • Data Storage and Cloud
  • Defense Tech
  • Diagnostics, Life Science Tools, and Deep Tech
  • Digital Health
  • Digital Media and Entertainment
  • Electronic Gaming
  • Fintech and Financial Services
  • FoodTech and AgTech
  • Global Generics
  • Internet
  • Life Sciences
  • Medical Devices
  • Mobile Devices
  • Mobility
  • NewSpace
  • Quantum Computing
  • Semiconductors
  • Software

  • Offices
  • Country Desks
  • Events
  • Community
  • Our Diversity
  • Sustainability
  • Our Values
  • Board of Directors
  • Management Team

  • Austin
  • Boston
  • Boulder
  • Brussels
  • Century City
  • Hong Kong
  • London
  • Los Angeles
  • New York
  • Palo Alto
  • Salt Lake City
  • San Diego
  • San Francisco
  • Seattle
  • Shanghai
  • Washington, D.C.
  • Wilmington, DE

  • Law Students
  • Judicial Clerks
  • Experienced Attorneys
  • Patent Agents
  • Business Professionals
  • Alternative Legal Careers
  • Contact Recruiting
Jose F. Martinez
Patent Agent
Patents and Innovations
Century City
jose.martinez@wsgr.com

D650-849-3429

Download vCard
Open PDF

Dr. Jose F. Martinez is a scientific advisor in the Century City office of Wilson Sonsini Goodrich & Rosati, where he is a member of the patents and innovations practice. His practice focuses on patent prosecution and intellectual property matters, primarily in the small-molecule pharmaceutical, 3D printing, clean technology, energy, computer network, and computer technology industries.

Prior to joining the firm, Jose conducted doctoral research on synthesizing and investigating photodriven carbon dioxide reduction catalysts under the supervision of Professor Michael R. Wasielewski at Northwestern University. During his time at Northwestern, he interned at Northwestern's Innovation and New Ventures, where he conducted and reviewed prior art and intellectual technical publications in order to advise on invention disclosures.

Experience

Dr. Jose F. Martinez is a scientific advisor in the Century City office of Wilson Sonsini Goodrich & Rosati, where he is a member of the patents and innovations practice. His practice focuses on patent prosecution and intellectual property matters, primarily in the small-molecule pharmaceutical, 3D printing, clean technology, energy, computer network, and computer technology industries.

Prior to joining the firm, Jose conducted doctoral research on synthesizing and investigating photodriven carbon dioxide reduction catalysts under the supervision of Professor Michael R. Wasielewski at Northwestern University. During his time at Northwestern, he interned at Northwestern's Innovation and New Ventures, where he conducted and reviewed prior art and intellectual technical publications in order to advise on invention disclosures.

Education
  • Ph.D., Chemistry, Northwestern University, 2018
  • B.A., Chemistry, Computer Science, Cornell College, 2013Recipient, American Chemical Society Scholar
Admissions
  • U.S. Patent and Trademark Office
Credentials
Education
  • Ph.D., Chemistry, Northwestern University, 2018
  • B.A., Chemistry, Computer Science, Cornell College, 2013Recipient, American Chemical Society Scholar
Admissions
  • U.S. Patent and Trademark Office

Select Publications

  • Co-author with N.T. La Porte and M.R. Wasielewski, "Electron Transfer from Photoexcited Naphthalene-1,4:5,8-bis(dicarboximide) Radical Anion to Mn(bpy)(CO) 3 X and Re(bpy)(CO) 3 X CO 2 Reduction Catalysts Linked via a Saturated Methylene Bridge," Journal of Photochemistry and Photobiology A: Chemistry, 2018
  • Co-author with A. Sinopoli, N.T. La Porte, M.R. Wasielewski, and M. Sohail, "Manganese carbonyl complexes for CO2 reduction," 365 Coordination Chemistry Reviews 60-74, 2018
  • Co-author with N.T. La Porte, S. Chaudhuri, S. Hedström, V.S. Batista, and M.R. Wasielewski, "Photoexcited radical anion super-reductants for solar fuels catalysis," 361 Coordination Chemistry Reviews 98-119, 2018
  • Co-author with N.T. La Porte and M.R. Wasielewski, "Electron Transfer from Photoexcited Naphthalene Diimide Radical Anion to Electrocatalytically Active Re(bpy)(CO)3Cl in a Molecular Triad," 122(5) The Journal of Physical Chemistry C 2608-17, 2018
  • Co-author with S. Hedström, S. Chaudhuri, N.T. La Porte, B. Rudshteyn, M.R. Wasielewski, and V.S. Batista, "Thousandfold Enhancement of Photoreduction Lifetime in Re(bpy)(CO)3 via Spin-Dependent Electron Transfer from a Perylenediimide Radical Anion Donor," 139(46) Journal of the American Chemical Society 16466-9, 2017
Insights

Select Publications

  • Co-author with N.T. La Porte and M.R. Wasielewski, "Electron Transfer from Photoexcited Naphthalene-1,4:5,8-bis(dicarboximide) Radical Anion to Mn(bpy)(CO) 3 X and Re(bpy)(CO) 3 X CO 2 Reduction Catalysts Linked via a Saturated Methylene Bridge," Journal of Photochemistry and Photobiology A: Chemistry, 2018
  • Co-author with A. Sinopoli, N.T. La Porte, M.R. Wasielewski, and M. Sohail, "Manganese carbonyl complexes for CO2 reduction," 365 Coordination Chemistry Reviews 60-74, 2018
  • Co-author with N.T. La Porte, S. Chaudhuri, S. Hedström, V.S. Batista, and M.R. Wasielewski, "Photoexcited radical anion super-reductants for solar fuels catalysis," 361 Coordination Chemistry Reviews 98-119, 2018
  • Co-author with N.T. La Porte and M.R. Wasielewski, "Electron Transfer from Photoexcited Naphthalene Diimide Radical Anion to Electrocatalytically Active Re(bpy)(CO)3Cl in a Molecular Triad," 122(5) The Journal of Physical Chemistry C 2608-17, 2018
  • Co-author with S. Hedström, S. Chaudhuri, N.T. La Porte, B. Rudshteyn, M.R. Wasielewski, and V.S. Batista, "Thousandfold Enhancement of Photoreduction Lifetime in Re(bpy)(CO)3 via Spin-Dependent Electron Transfer from a Perylenediimide Radical Anion Donor," 139(46) Journal of the American Chemical Society 16466-9, 2017

Therapeutics and Drug Discovery

  • Drug conjugates
  • Small molecules

Chemistry and Material Science

  • Organic chemistry
Technical Fluency

Therapeutics and Drug Discovery

  • Drug conjugates
  • Small molecules

Chemistry and Material Science

  • Organic chemistry
Focus Areas
  • Intellectual Property
  • Life Sciences
  • Patents and Innovations
Recent Insights
Client Highlights
Wilson Sonsini Advises Aeovian Pharmaceuticals on Patent Matters Related to $55 Million Series B Financing
On December 16, 2025, Aeovian Pharmaceuticals, a clinical-stage biopharmaceutical company developing highly selective small molecule therapeutics that restore cellular metabolic quality control, announced it has closed an oversubscribed $55 million Series B financing that will fund completion of a Phase 2 proof-of-concept study for its lead development candidate, AV078, in tuberous sclerosis complex (TSC)-related refractory epilepsy. Proceeds from the financing will support the advancement of AV078 into a Phase 2 proof-of-concept study in participants with TSC-refractory epilepsy. Wilson Sonsini Goodrich & Rosati advised Aeovian Pharmaceuticals on patent matters related to the transaction.
Learn More
Client Highlights
Wilson Sonsini Advises Solve Therapeutics on Patent Matters Related to $120 Million Financing
On November 17, 2025, Solve Therapeutics, a clinical-stage biotechnology company developing best-in-class antibody-drug conjugates (ADCs) for solid tumor malignancies, announced it raised $120 million in an oversubscribed and upsized financing to accelerate the development of its clinical pipeline and proprietary CloakLink™ linker platform. This latest funding follows a $75 million financing completed in December 2024, bringing Solve’s total capital raised to $321 million. Wilson Sonsini Goodrich & Rosati advised Solve Therapeutics on patent matters related to the transaction.
Learn More
View All
  • people
  • insights
  • about us
  • careers
  • Binder
  • Alumni
  • Mailing List Signup
  • Client FTP Portal
  • Privacy Policy
  • Terms of Use
  • Accessibility
WSGR logo
Twitter
LinkedIn
Facebook
Instagram
Youtube
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.